The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

During the study, patients will receive Saruparib tablets with a maximum daily dose of 60 milligrams. The treatment can continue for up to 24 months depending on how the disease responds and how well the treatment is tolerated. Patients will need to have tissue samples from their tumor available, either from previous biopsies or surgeries, or they may need to have a new biopsy taken. These samples are needed to confirm the genetic changes in the cancer cells. Regular assessments will be done to measure the size of the tumors and check how the cancer is responding to treatment.

The study will monitor patients for any side effects or unwanted reactions that may occur during treatment. Blood tests and other medical examinations will be performed regularly to ensure patients’ organs are functioning properly and to track their overall health. Quality of life will also be assessed using questionnaires to understand how the treatment affects patients’ daily activities and well-being. The study will measure how many patients respond to the treatment, how long the responses last, how long patients live without the cancer getting worse, and overall survival.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

The purpose of this study is to evaluate how well olaparib works in patients with metastatic pancreatic cancer that has responded to or remained stable with chemotherapy. The study will look at different groups of patients: those who have certain genetic changes in genes related to DNA repair (such as BRCA1, BRCA2, or other genes involved in a process called homologous recombination) and those who do not have these changes or whose genetic status is unknown. Patients will receive olaparib as a maintenance treatment, meaning it is given to help keep the cancer under control after the initial chemotherapy has been completed. The study will track how long patients survive, how long the cancer remains controlled without getting worse, and whether the cancer shrinks or disappears.

During the study, patients will take olaparib tablets for up to 36 months. Regular check-ups will include imaging scans using CT or MRI to monitor the cancer, blood tests to check organ function and blood cell counts, and assessments of side effects. Quality of life will also be measured using questionnaires that ask about symptoms like pain, tiredness, nausea, weight loss, and overall wellbeing. The study will also collect tissue samples and genetic information to better understand which patients might benefit most from this treatment and to explore connections between specific genetic changes and how well the treatment works.

Patients in the study will receive ASP3082 for up to 8 weeks. During this time, doctors will check how the tumors respond to the treatment using imaging scans. The study will also involve taking samples from the tumor and blood at different times to understand how the treatment is working and why some tumors might stop responding to it. Patients with lung cancer must have already tried other standard treatments, including chemotherapy with platinum-based drugs and immunotherapy, and their cancer must have gotten worse. Patients with pancreatic cancer must have received one prior chemotherapy treatment that lasted at least 5 months before their disease progressed.

The study will measure several things to understand if the treatment is helpful. Doctors will look at whether tumors shrink or stop growing, how long any response lasts, and how long patients live without their cancer getting worse. They will also carefully track any side effects that occur during treatment. The study will examine changes in the body and in the tumor samples to learn more about how ASP3082 affects cancer cells and why some cancers might develop resistance to the treatment over time.

The study uses several chemotherapy medications including gemcitabine, paclitaxel, fluorouracil, irinotecan, oxaliplatin, and folinic acid. Some patients will receive a combination of gemcitabine and paclitaxel, while others will receive a combination of the other medications. The choice of treatment will be based on specific genetic patterns found in the tumor tissue.

The treatment involves receiving chemotherapy for 4 months before surgery. After surgery, patients will continue to be monitored to evaluate how well the treatment worked. Throughout the study, doctors will track various measures of treatment success, including whether the cancer returns and how long patients live without the disease getting worse.

The study involves several chemotherapy medications that are commonly used to treat pancreatic cancer. These include capecitabine, paclitaxel, irinotecan, gemcitabine, fluorouracil, oxaliplatin, and calcium folinate. Some medications are given by mouth, while others are administered through an intravenous line. The treatment period typically lasts for 6 months.

The research is divided into two parts. The first part checks if it’s possible to grow these mini-tumors and test different chemotherapy combinations on them within 12 weeks after surgery. The second part examines how well patients do when their treatment is chosen based on how their laboratory-grown tumor responds to different chemotherapy combinations. The effectiveness of the treatment will be measured by tracking how long patients remain free of cancer after treatment.

The study aims to test how well patients respond to these treatments and determine the safest and most effective doses. The main treatment being studied is a radioactive drug called [177Lu]Lu-FAP-2286, which will be given either alone or in combination with other cancer medications. This drug works by targeting specific proteins found in cancer cells.

During the study, patients will receive their assigned treatments through intravenous infusion, which means the medications are given directly into a vein. Doctors will monitor patients’ responses to treatment and track any side effects that may occur. The study includes different treatment groups depending on the type of cancer and previous treatments patients have received.

The purpose of this research is to understand how safe AZD4360 is and how well it works in treating these types of cancer. The study will also examine how the medication moves through the body over time. The medication will be given to patients whose cancer has a specific characteristic called CLDN18.2 expression and who have already received at least one previous treatment for their cancer.

This is a combined Phase 1 and Phase 2 study, which means it will first determine the safest dose of the medication and then test how effective it is at treating these cancers. During the study, participants will receive AZD4360 and undergo various medical assessments to monitor their health and the medication’s effects. The treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.

The PET/CT (Positron Emission Tomography/Computed Tomography) scan being studied uses a substance called 68Ga-FAPI-46, which is a radioactive tracer that attaches to certain proteins found in cancer cells. This allows doctors to potentially see cancer that might be missed by conventional imaging techniques. The purpose of the study is to evaluate whether this imaging method can detect additional cancer spread that would change the treatment approach for patients.

Participants in this study will undergo standard diagnostic tests as well as the additional 68Ga-FAPI-46 PET/CT scan. Researchers will compare the results of standard imaging with the results after adding the new PET/CT technique to see if it leads to changes in the cancer’s staging or treatment plan. The study will separately analyze results for pancreatic cancer and bile duct cancer patients.

The study is divided into two main steps. In the first step, patients receive a combination of NALIRIFOX and 5-FU (a form of Fluorouracil) to see if this approach can help control the cancer for at least six months. In the second step, the study looks at whether adding the antibiotic Ciprofloxacin to a Gemcitabine-based treatment can help patients live longer. The study is designed to be non-comparative and randomized, meaning that participants are randomly assigned to different treatment groups to ensure unbiased results.

Participants in the study will receive their treatments through infusions, which are administered directly into the bloodstream. The study will monitor the patients’ health and response to the treatments over a period of time, with regular check-ups and assessments. The goal is to find the most effective treatment strategy for patients with this type of pancreatic cancer, potentially improving their quality of life and survival rates.

The trial will involve the use of two main treatments. The first is [18F]FAPI-74, a solution for injection that helps in imaging cancer cells. The second is Telebrix Gastro, a solution taken orally or rectally, which is used as a bowel opacifier to improve imaging results. The study will compare the effectiveness of these treatments in detecting cancer in newly diagnosed patients who have not yet received treatment. The goal is to determine if the new imaging method can provide better information about the cancer, which could help in planning the best treatment approach.

Participants in the study will undergo imaging tests using the new method, and the results will be compared to those from standard imaging techniques. The study will take place over a period of time, with the aim of gathering enough data to understand the benefits of the new imaging method. This research could potentially lead to improved ways of diagnosing and managing cancer, providing doctors with more accurate information to guide treatment decisions.

The purpose of the study is to learn more about the safety and potential benefits of AZD0022 for people with these cancers. Participants will receive the medication and be monitored to see how their bodies respond. Some participants may receive AZD0022 alone, while others may receive it alongside other cancer drugs. The study will also look at how the drug moves through the body over time. This information will help researchers understand the best way to use AZD0022 in treating these cancers.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their cancer. The study will also collect information on any side effects experienced by participants. This trial is an important step in finding new ways to treat cancers with the KRAS-G12D mutation and could lead to new treatment options for patients in the future.

The purpose of the study is to assess the safety and tolerability of these treatments in patients with advanced or metastatic PDAC. The study will be conducted in two phases. In the first phase, the focus will be on determining how safe the treatments are and how well patients can tolerate them. In the second phase, the study will continue to monitor safety and will also look at how effective the treatments are in fighting the cancer. Patients will receive the treatment through an IV infusion, which means the medicine is given directly into a vein.

Throughout the study, patients will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to find out if these new treatments can help control the cancer and improve the quality of life for patients with PDAC. The trial will also explore how long the modified T-cells stay active in the body and how they affect the cancer over time. This research is important for developing new ways to treat pancreatic cancer, especially for those with specific genetic markers like the KRAS mutation.

The purpose of the study is to evaluate the overall survival of patients who undergo a specific treatment sequence. This sequence includes initial treatment with a combination of chemotherapy drugs known as mFOLFIRINOX and radiotherapy, followed by surgery to remove the cancer, and then additional chemotherapy. The study will compare the survival data of these patients with those who receive surgery followed by mFOLFIRINOX chemotherapy without the initial treatment.

Participants in the study will follow a treatment plan over a period of time, with regular monitoring to track their progress. The study aims to gather information on how long patients live after starting treatment, as well as other factors such as the time they remain free from invasive disease, the number of treatment cycles completed, and any new symptoms or side effects that may occur. The study will also assess the quality of life of participants using a questionnaire. The goal is to better understand the effectiveness of the treatment plan and improve outcomes for patients with resectable pancreatic cancer.

The purpose of the study is to find out if the new treatment is safe and to determine the best dose to use. Patients will receive the treatment through injections guided by ultrasound, a technique that uses sound waves to create images of the inside of the body. The study will start with a small dose of RR001 and gradually increase it to find the highest dose that can be given safely. The study will also look at how well the treatment works in shrinking the tumor and improving the patient’s quality of life.

Participants in the study will receive the treatment over a period of time and will be monitored closely by doctors. They will have regular check-ups, including imaging tests like CT scans to see how the tumor is responding to the treatment. The study will also track how long it takes for the disease to progress and how long patients live after receiving the treatment. The goal is to improve the outcomes for patients with this challenging type of cancer.

Participants in the study will receive either the FOLFOX treatment or the gemcitabine treatment. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of up to 24 months, during which the participants will be monitored regularly to assess their response to the treatment. The main goal is to evaluate the overall survival of patients over this period. Additionally, the study will look at other factors such as the response rate to the treatment, the duration of disease control, and any side effects experienced by the participants.

Throughout the study, various assessments will be conducted, including imaging tests like CT scans or MRI to monitor the cancer’s progression. Blood tests will also be performed to check levels of certain markers like Ca 19-9 and CEA, which can provide information about the cancer’s activity. The study will also evaluate the quality of life of participants using questionnaires. The information gathered from this trial will help determine the best treatment option for patients with pancreatic adenocarcinoma who are not fit for FOLFIRINOX.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

Participants in the study will receive treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the participants over time to assess how well they tolerate the treatment and to observe any changes in their cancer. The trial will also look at how the body processes AZD0901 and whether the immune system reacts to it. The study aims to gather information on the overall survival of participants, how long they live without the cancer getting worse, and how long any positive response to the treatment lasts.

Throughout the study, researchers will collect data on the size of the tumors and any changes that occur. They will also investigate the relationship between certain genetic or protein markers in the tumors and the effectiveness of the treatment. This information will help determine if AZD0901 could be a beneficial treatment option for patients with these types of cancers. The study is expected to continue until 2027, with recruitment of participants starting in late 2024.

The purpose of this study is to evaluate the safety and effectiveness of PBP1510 when given alone and in combination with gemcitabine. The study is divided into two parts. In the first part, the focus is on understanding how safe and tolerable PBP1510 is for patients. In the second part, the study aims to determine how effective the treatment is when used with gemcitabine. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, patients will be monitored for any side effects and how their bodies respond to the treatment. The study will also look at how the treatment affects the cancer and whether it helps in reducing the size of the tumors. This research is important for developing new treatment options for patients with pancreatic cancer who have not responded to previous chemotherapy treatments.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

The purpose of the study is to determine if adding BNT321 to the standard mFOLFIRINOX treatment improves outcomes for patients. The study will be conducted in two phases. In the first phase, the focus will be on assessing the safety of BNT321 when used with mFOLFIRINOX and determining the appropriate dose for the second phase. The second phase will compare the effectiveness of mFOLFIRINOX with BNT321 against mFOLFIRINOX alone in preventing the return of cancer after surgery.

Participants in the trial will receive the treatments through intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein. The study will monitor patients for any side effects and measure how long they remain free of cancer after treatment. The trial aims to provide valuable information on whether the addition of BNT321 can offer better protection against the recurrence of pancreatic cancer following surgery.

The study is divided into two phases. In the first phase, participants will receive different doses of IPN01194 to determine the safest and most effective dose. This phase will also monitor any side effects that may occur. In the second phase, the study will focus on how well the treatment works in reducing the size of the tumors. Participants will be closely monitored throughout the study to assess their response to the treatment and any changes in their condition.

Participants in the study will receive either the medication IPN01194 or a placebo. The study aims to gather information on how the body processes the medication and its impact on the tumors. This information will help researchers understand the potential benefits and risks of IPN01194 for treating these types of cancers. The study is expected to continue for several years to ensure comprehensive data collection and analysis.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of this study is to evaluate how well the combination of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX works compared to mFOLFIRINOX alone, by looking at how long patients remain free of cancer after treatment. Participants in the study will be randomly assigned to receive either the combination treatment or mFOLFIRINOX alone. The study will last for up to 12 months, during which participants will receive their assigned treatment and be monitored for any side effects and the effectiveness of the treatment.

Throughout the study, participants will undergo regular check-ups, including imaging tests like MRI or CT scans, to assess the status of their cancer. The study aims to provide valuable information on whether adding Autogene Cevumeran and Atezolizumab to the standard mFOLFIRINOX treatment can improve outcomes for patients with pancreatic ductal adenocarcinoma. This research could potentially lead to new treatment options for this type of cancer.

The study will be conducted in two main parts. In the first part, the treatment will be given alone to see how patients tolerate it and to determine the best dose. In the second part, the treatment will be combined with standard cancer treatments to see if it works better together. Throughout the study, researchers will monitor patients closely to ensure their safety and to gather information on how the treatment affects their cancer.

Participants in the study will take the treatment in the form of a tablet by mouth. The study will involve regular check-ups and tests to track the treatment’s effects and any side effects. The goal is to find out if GTAEXS617 can be a safe and effective option for treating advanced solid tumors.

Participants in the study will receive treatment over a period of up to 16 weeks. The medications involved in the study include Fluorouracil, Gemcitabine, Folinic Acid, Irinotecan Hydrochloride Trihydrate, Oxaliplatin, and Paclitaxel. These medications are administered through an infusion, which means they are delivered directly into the bloodstream. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment.

The study aims to determine the effectiveness of the treatments in achieving a successful surgical removal of the tumor and improving the time patients remain free from the disease. It will also assess other factors such as the rate of tumor removal, the time without cancer spreading, and the overall survival of participants. The trial will help in understanding the potential benefits and risks of combining chemotherapy with radiation therapy for treating pancreatic cancer.

The purpose of the study is to find out how safe and effective SOT102 is for patients with advanced stages of these cancers. The study will be conducted in several parts. Initially, it will determine the best dose of SOT102 that can be given safely. Later, it will assess how well the treatment works in shrinking or controlling the cancer. Patients will receive the treatment through an intravenous infusion, which means the medicine will be given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. The trial aims to provide valuable information on whether SOT102 can be a beneficial treatment option for people with these types of cancer. The study is expected to continue until early 2026, with the hope of improving treatment options for patients with gastric and pancreatic adenocarcinoma.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

Participants in the study will undergo repeated PET-CT scans, which combine PET imaging with computed tomography (CT) to provide a comprehensive view of the cancer. These scans will be done at the start of the study and at various points during the trial. The study aims to see if the images can help identify specific markers that indicate how the cancer might progress or respond to treatment. This could potentially lead to earlier and more accurate diagnosis and monitoring of pancreatic cancer.

The trial will track the time from diagnosis to any changes in the disease, such as progression or recurrence, as well as the time from surgery to any return of the disease. These outcomes will be assessed using routine CT scans, which are typically done every three months, although additional scans may be performed if needed. The study will continue until 2027, with the goal of improving the understanding and management of pancreatic cancer through advanced imaging techniques.